Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from
FinraMoving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.
Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.
Mark Hahn, the Chief Financial Officer of Verona Pharma PLC (NASDAQ:VRNA), executed a significant transaction on August 13, 2024, where the insider sold 400,000 shares of the company. Following this transaction, the insider now owns 14,939,688 shares of Verona Pharma PLC. Verona Pharma PLC is a biopharmaceutical company focused on developing and commercializing innovative therapies for the treatment of respiratory diseases.
We recently compiled a list of the Top 10 Holdings of Caligan Partners. In this article, we are going to take a look at where Verona Pharma plc (NASDAQ:VRNA) stands against Caligan Partners’ other top holdings. Founded in 2017, Caligan Partners is one of the most significant specialty hedge funds. David Johnson is the brainchild behind […]
OhtuvayreTM (ensifentrine) now available; patient shipments started Strong balance sheet supports commercialization and pipeline expansion Conference call today at 9:00 a.m. EDT / 2:00 p.m. BST LONDON and RALEIGH, N.C., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), a biopharmaceutical company focused on respiratory diseases, announces its financial results for the second quarter ended June 30, 2024, and provides a corporate update. “We are
With the business potentially at an important milestone, we thought we'd take a closer look at Verona Pharma plc's...
LONDON and RALEIGH, N.C., July 30, 2024 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”) announces that senior management will present a company overview at the 44th Annual Canaccord Growth Conference on Tuesday, August 13, 2024, at 1:30 p.m. EDT / 6:30 p.m. BST. A webcast of the event will be available on the Events and Presentations link on the Investors page of the Company’s website, www.veronapharma.com. For further information please contact: Verona Ph
LONDON and RALEIGH, N.C., July 25, 2024 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”) announces that it will report its financial results for the second quarter ended June 30, 2024 on Thursday, August 8, 2024 and host an investment community conference call at 9:00 a.m. EDT / 2:00 p.m. BST to discuss these financial results and provide a corporate update. To participate, please dial one of the following numbers and ask to join the Verona Pharma call: +1-
Verona Pharma (VRNA) surges on the recent FDA approval for its lead drug, which is the first inhaled COPD product with a novel mechanism of action in more than 20 years.
Ohtuvaye is expected to rake in $1.1bn in global sales from the market for COPD patients with moderate to severe exacerbations by 2029.
On Wednesday, the FDA approved Verona Pharma plc’s (NASDAQ:VRNA) Ohtuvayre (ensifentrine) for the maintenance treatment of chronic obstructive pulmonary disease (COPD) in adult patients. Ohtuvayre is the first inhaled product with a novel mechanism of action available for the maintenance treatment of COPD in more than 20 years. Related: Verona Pharma’s Promising COPD Treatment Puts It in GSK’s Acquisition Crosshairs, Analysts Predict Big Moves. Ohtuvayre is a first-in-class selective dual inhibi
Ohtuvayre improved dyspnea compared to placebo in as little as six weeks and maintained this over 24 weeks.